|Mr. Daniel Marcel Legault||Pres, CEO, Sec. & Director||273k||N/A||1958|
|Dr. John Lawrence Wallace||Founder, Chief Scientific Officer & Director||273k||N/A||1957|
|Mr. Alain Wilson MBA||Chief Financial Officer||48k||N/A||N/A|
|Mr. Scott Curtis M.Eng, CFA||VP of Corp. Devel.||95k||N/A||N/A|
|Dr. David James Vaughan Ph.D.||Chief Devel. Officer||N/A||N/A||1950|
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Antibe Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.